Clinical trials: Stereotactic Body Radiation Therapy
Cholangiocarcinoma, Hepatobiliary Neoplasm
Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation
The purpose of this study is to determine progression-free survival at 12 months for stereotactic body radiotherapy (SBRT) and chemotherapy for unresectable hilar cholangiocarcinoma (CCA).
- Conditions
- Cholangiocarcinoma, Hepatobiliary Neoplasm, Liver Cancer, Bile Duct Cancer
- Trial name
- NCT01151761
- Testing
- Stereotactic Body Radiotherapy, Gemcitabine, Cisplatin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Stanford University
Pancreatic Cancer
GTX-RT in Borderline Resectable Pancreatic Cancer
The purpose of this study is to find out if a program of intensive chemotherapy with gemcitabine, docetaxel and capecitabine followed by an advanced form of focused radiation aimed at participant's tumor followed by more…
- Trial name
- NCT01754623
- Testing
- Capecitabine, Gemcitabine, Docetaxel
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma
A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer
This pilot clinical trial studies the side effects of stereotactic body radiation therapy and pazopanib hydrochloride in treating patients with kidney cancer who are not able to undergo surgery.
- Trial name
- NCT02307474
- Testing
- Stereotactic Radiosurgery, Pazopanib Hydrochloride
- Where
- 2 sites in United States
- Sponsor
- Case Comprehensive Cancer Center
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing Neurocognitive Decline and Improving Survival in Patients With Brain Metastases From Breast or Lung Cancer
This clinical trial tests the effectiveness of an interactive time-restricted diet intervention (txt4fasting) in reducing neurocognitive decline and improving survival outcomes after stereotactic radiosurgery in patients with…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Carcinoma, Metastatic Malignant Neoplasm in the Brain
- Trial name
- NCT06315296
- Testing
- Behavioral Dietary Intervention, Text Message-Based Navigation Intervention, Internet-Based Intervention
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Thomas Jefferson University
Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC
This phase I trial studies the side effects of atezolizumab, varlilumab, and radiation therapy in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced) and cannot be removed by…
- Trial name
- NCT04081688
- Testing
- Atezolizumab 1200 MG in 20 ML Injection, Stereotactic Body Radiation Therapy, Varlilumab 3 mg/kg
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Rutgers, The State University of New Jersey
Lung Cancer
Image Guided and Breathing Adapted Radiotherapy of Early Stage Lung Cancer
The purpose of this study is to quantify the variation in tumour middle position during a course of stereotactic body radiotherapy (SBRT), and thereby be able to design radiotherapy margins that takes into account the full motion…
- Trial name
- NCT00910546
- Testing
- visicoil gold marker 0.7 x 20 mm
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- Gitte Fredberg Persson
Benign Prostatic Hyperplasia
Urolift Pre-SBRT for Reduced Urinary Toxicity in Patients With BPH and Prostate Cancer.
Many patients may face long-term urinary side effects following stereotactic body radiation therapy (SBRT), including increased urinary frequency, dysuria, and nocturia.
- Trial name
- NCT05148156
- Testing
- Urolift
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Brain Metastases
Evaluation of Brain Metastases Treated With Stereotactic Radiotherapy Using Dynamic [18F]FDG PET
The purpose of this study is to evaluate the clinical usefulness of dynamic [18F]FDG PET imaging in assessing brain metastasis post stereotactic radiotherapy to separate true progression from the treatment-related changes.
- Trial name
- NCT06511323
- Testing
- dynamic [18-FDG PET] scan post stereotactic radiation for brain metastases
- Volunteers
- 70 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Glioblastoma, Glioblastoma Multiforme
Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma
The goal of this clinical trial is to evaluate the safety and efficacy of neoadjuvant radiochemotherapy in the surgical resection of glioblastoma (GBM).
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype, Radiotherapy; Complications
- Trial name
- GLINERA (NCT06418113)
- Testing
- hypofractionated stereotactic radiotherapy, Stereotactic biopsy, resection
- Where
- Spain
- Volunteers
- 12 people
- Sponsor
- Hospital San Carlos, Madrid
Epilepsy
Precision Radiation Treatment for Epilepsy (PRECISION)
The PRECISION-study offers a non-invasive, curative intervention for drug-resistant localised epilepsy patients who are not eligible for surgery.
- Trial name
- PRECISION (NCT05182437)
- Testing
- LINAC-based Stereotactic Radiotherapy
- Where
- Netherlands
- Volunteers
- 94 people
- Sponsor
- Maastricht Radiation Oncology
Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma
Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.
The purpose of this study is to evaluate if the combination of nivolumab and a CCR2/CCR5 dual antagonist (BMS-813160) with GVAX is safe in patients with locally advanced pancreatic cancer (LAPC) who have received chemotherapy and…
- Trial name
- NCT03767582
- Testing
- Stereotactic Body Radiation (SBRT), Nivolumab, CCR2/CCR5 dual antagonist
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Prostate Cancer
Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer
This study is to find out whether adding the study drug atezolizumab and stereotactic body radiotherapy (SBRT) to standard treatment with abiraterone acetate, prednisone, and Lupron® (leuprolide) is a safe and effective way to…
- Trial name
- NCT04262154
- Testing
- Atezolizumab, Abiraterone, Prednisone
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lung Cancer
SABR for T1-2a N1 NSCLC
Conventionally fractionated radiation therapy given over 6-7 weeks alone, sequentially, or concurrent with chemotherapy have produced poor outcomes in Stage II NSCLC in most series.
- Trial name
- NCT03321760
- Testing
- Stereotactic Ablative Radiation Therapy (SABR)
- Where
- 3 sites in United States
- Sponsor
- Indiana University
Brain Metastases
Magnetic Resonance Imaging-guided Adaptive Radiotherapy for Large Brain Metastases
This study is an ambispective cohort study to evaluate the displacement and deformation of large brain metastases (BM) treated with magnetic resonance imaging-guided adaptive radiotherapy (MRIgART)
- Trial name
- NCT06405256
- Testing
- magnetic resonance imaging-guided adaptive radiotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Luminal B
Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:
Neo-CheckRay is a multicenter, open-label phase II study that randomizes luminal B breast cancer subjects candidate for neo-adjuvant chemotherapy in a 1:1:1 ratio in 3 arms: 1.
- Trial name
- Neo-CheckRay (NCT03875573)
- Testing
- Durvalumab, Stereotactic Body Radiotherapy, Oleclumab
- Where
- 7 sites in Belgium, France
- Volunteers
- 147 people
- Sponsor
- Jules Bordet Institute
Oligometastatic Hormone Sensitive Prostate Cancer
APalutamiAPalutamide and stEReotactic Body Radiation Therapy for Metastatic Prostate Cancer
Final results from TITAN trial showed that apalutamide plus ADT improved OS in a population of patients with metastatic hormone sensitive prostate cancer (mHSPC), if compared to ADT alone.
- Trial name
- PERSIAN (NCT05717660)
- Testing
- SBRT on all sites of metastatic disease+Apalutamide
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Brain
Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors
This phase III trial studies the side effects and how well stereotactic radiosurgery (SRS) works before or after surgery in patients with tumors that has spread to the brain or that can be removed by surgery.
- Trial name
- NCT03750227
- Testing
- Conventional Surgery, Questionnaire Administration, Stereotactic Radiosurgery
- Where
- 4 sites in United States
- Volunteers
- 140 people
- Sponsor
- Mayo Clinic
Unresectable Melanoma, Metastatic Melanoma
A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma
This is a multicenter, open label, Phase 2 study, with 3 parallel cohorts. The aim of the study is to evaluate the efficacy of sotigalimab (APX005M) administered at 2 different schedules to adult participants with unresectable or…
- Conditions
- Unresectable Melanoma, Metastatic Melanoma, Cancer, Cancer of Skin
- Trial name
- NCT04337931
- Testing
- sotigalimab
- Where
- 19 sites in Poland, Spain
- Volunteers
- 45 people
- Sponsor
- Apexigen America, Inc.
Prostate Cancer, Breast Cancer
Immune Responses in Prostate, Lung, Melanoma and Breast Cancer Patients Following Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT) or Brachytherapy
Success of cancer immunotherapy is limited by the ability of solid tumors to evade local and systemic antitumoral immune responses.
- Conditions
- Prostate Cancer, Breast Cancer, Lung Cancer, Melanoma
- Trial name
- SBRT (NCT01777802)
- Testing
- SBRT, IMRT, Brachytherapy
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Mayo Clinic
Early Stage Non-Small Cell Lung Cancer
SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)
The purpose of the study is to determine whether avelumab has an effect on cancer and body in combination with SBRT, a standard treatment for early stage non-small cell lung cancer (NSCLC).
- Trial name
- NCT03050554
- Testing
- Avelumab, SBRT
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Andrew Sharabi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.